Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name ALPN-202
Synonyms
Therapy Description

ALPN-202 is a fusion protein consisting of the N-terminal Ig variable-like (IgV) domain of CD80 fused to an immunoglobulin G1 (IgG1) Fc fragment that inhibits programmed cell death-1 ligand 1 (PD-L1; CD274) and CTL-associated antigen 4 (CTLA4) signaling and activates PD-L1-dependent CD28 signaling, which potentially leads to immune checkpoint inhibition and increased antitumor immune response (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2547-2547).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ALPN-202 ALPN 202|ALPN202|CD80 vIgD-Fc Fusion Protein ALPN-202 CTLA4 Inhibitor 4 Immune Checkpoint Inhibitor 149 PD-L1 Inhibitor 13 ALPN-202 is a fusion protein consisting of the N-terminal Ig variable-like (IgV) domain of CD80 fused to an immunoglobulin G1 (IgG1) Fc fragment that inhibits programmed cell death-1 ligand 1 (PD-L1; CD274) and CTL-associated antigen 4 (CTLA4) signaling and activates PD-L1-dependent CD28 signaling, which potentially leads to immune checkpoint inhibition and increased antitumor immune response (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2547-2547).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04186637 Phase I ALPN-202 An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1) Terminated USA | AUS 0


Additional content available in CKB BOOST